Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing
Summarize this article with:
Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(19min)Comments(2)SummaryKyverna Therapeutics (KYTX) is upgraded to "Strong Buy" following positive phase 2 data for miv-cel in SPS and MG indications.Company achieved a 46% average improvement in SPS patients in phase 2 KYSA-8 study, surpassing clinical benchmarks of 20% improvement, and plans a BLA filing for SPS in 1H 2026.Phase 3 portion enrollment of phase 2/3 KYSA-6 registrational study for miv-cel in Myasthenia Gravis is set for end of 2025, with updated phase 2 portion data expected in 2026.Company's cash runway extends into 2027 with recent financing, but risks remain regarding regulatory acceptance of single-arm data and small sample sizes. gentlelight/iStock via Getty Images The last time I wrote about Kyverna Therapeutics (KYTX) it was with respect to a Seeking Alpha article entitled "Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025". With respect to this article, I noted thatThis article was written byTerry Chrisomalis14.53K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.